Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Cervical Cancer | Primary research

FENDRR suppresses cervical cancer proliferation and invasion by targeting miR-15a/b-5p and regulating TUBA1A expression

Authors: Yunheng Zhu, Xiaohua Zhang, Lifeng Wang, Xiuxiang Zhu, Ziyin Xia, Ling Xu, Jun Xu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Previous literature has revealed long non-coding RNAs (lncRNAs) are crucial regulators for cell functions and gene expression. LncRNA fetal-lethal non-coding developmental regulatory RNA (FENDRR) was reported as a biological suppressor in several types of human cancers, yet relevant mechanisms and biological effects of FENDRR with regards to cervical cancer (CC) are not explored until now.

Methods

In this study, quantitative real-time polymerase chain reaction (qRT-PCR) analysis detected gene expression in tissues and cells. Gain- or loss-of-function experiments revealed the biological effects of FENDRR and miR-15a/b-5p on CC cell functions. Bioinformatics tools were used to predict the relevant genes. Mechanism experiments including RNA immunoprecipitation (RIP) assay, pull down assay and luciferase reporter assay depicted the binding situation and coexistence of indicated genes.

Results

FENDRR was downregulated in CC tissues and cells, which suppressed CC progression. MiR-15a-5p and miR-15b-5p shared binding sites with FENDRR and had interaction with FENDRR. Tubulin alpha1A (TUBA1A) was downregulated in CC tissues and positively modulated by FENDRR. TUBA1A was the target of miR-15a/b-5p. TUBA1A silencing rescued the effect of FENDRR overexpression on CC cell growth and migration.

Conclusion

FENDRR inhibits CC progression through upregulating TUBA1A in a miR-15a/b-5p-dependent manner.
Appendix
Available only for authorised users
Literature
1.
Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A, Galazios G. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320–5.PubMed
2.
Khan SR, Rockall AG, Barwick TD. Molecular imaging in cervical cancer. Q J Nucl Med Mol Imaging. 2016;60(2):77–92.PubMed
3.
Tsu V, Jeronimo J. Saving the world’s women from cervical cancer. N Engl J Med. 2016;374(26):2509–11.CrossRefPubMed
4.
Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol. 2017;39(7):1010428317711315.PubMed
5.
Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925–33.CrossRefPubMed
6.
Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.CrossRefPubMed
7.
Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(17):3850–6.PubMed
8.
Zhang M, Wu WB, Wang ZW, Wang XH. lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. Eur Rev Med Pharmacol Sci. 2017;21(5):1020–6.PubMed
9.
Wang B, Xian J, Zang J, Xiao L, Li Y, Sha M, Shen M. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression. Biochem Biophys Res Commun. 2019;509(1):143–7.CrossRefPubMed
10.
Qin X, Lu M, Zhou Y, Li G, Liu Z. LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells. Cell Cycle. 2019;18(8):889–97.CrossRefPubMedPubMedCentral
11.
Li Y, Zhang W, Liu P, Xu Y, Tang L, Chen W, Guan X. Long non-coding RNA FENDRR inhibits cell proliferation and is associated with good prognosis in breast cancer. OncoTargets Ther. 2018;11:1403–12.CrossRef
12.
Zhang MY, Zhang ZL, Cui HX, Wang RK, Fu L. Long non-coding RNA FENDRR inhibits NSCLC cell growth and aggressiveness by sponging miR-761. Eur Rev Med Pharmacol Sci. 2018;22(23):8324–32.PubMed
13.
Liu J, Du W. LncRNA FENDRR attenuates colon cancer progression by repression of SOX4 protein. OncoTargets Ther. 2019;12:4287–95.CrossRef
14.
Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z, Li J. Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. Biomarkers. 2018;23(5):435–45.CrossRefPubMed
15.
Wen Q, Liu Y, Lyu H, Xu X, Wu Q, Liu N, Yin Q, Li J, Sheng X. Long noncoding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer. 2017;27(6):1096–108.CrossRefPubMedPubMedCentral
16.
Guo H, Yang S, Li S, Yan M, Li L, Zhang H. LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer. Biomed Pharmacother. 2018;102:749–57.CrossRefPubMed
17.
Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018;29(6):e95.CrossRefPubMedPubMedCentral
18.
Wang YF, Zhang S, Li XQ, Wang Y. Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival. Eur Rev Med Pharmacol Sci. 2016;20(19):3987–91.PubMed
19.
Yu Z, Zhao H, Feng X, Li H, Qiu C, Yi X, Tang H, Zhang J. Long non-coding RNA FENDRR acts as a miR-423-5p sponge to suppress the Treg-mediated immune escape of hepatocellular carcinoma cells. Mol Ther Nucleic Acids. 2019;17:516–29.CrossRefPubMedPubMedCentral
20.
Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T, Shi X, Li J, Li X. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. 2016;7(39):64148–67.PubMedPubMedCentral
21.
Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao WZ, Peng H, Hong WW, Yin LH, Pu YP, et al. Integrated analysis of long non-coding RNA associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol. 2016;49(5):2023–36.CrossRefPubMed
22.
Fu C, Li D, Zhang X, Liu N, Chi G, Jin X. LncRNA PVT1 facilitates tumorigenesis and progression of glioma via regulation of MiR-128-3p/GREM1 axis and BMP signaling pathway. Neurotherapeutics. 2018;15(4):1139–57.CrossRefPubMedPubMedCentral
23.
24.
Kontos CK, Tsiakanikas P, Avgeris M, Papadopoulos IN, Scorilas A. miR-15a-5p, a novel prognostic biomarker, predicting recurrent colorectal adenocarcinoma. Mol Diagn Ther. 2017;21(4):453–64.CrossRefPubMed
25.
Chen H, Tian Y. MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA. Biosci Trends. 2017;10(6):482–8.CrossRefPubMed
26.
Gao P, Si J, Yang B, Yu J. Upregulation of microRNA-15a contributes to pathogenesis of abdominal aortic aneurysm (AAA) by modulating the expression of cyclin-dependent kinase inhibitor 2B (CDKN2B). Med Sci Monit. 2017;23:881–8.CrossRefPubMedPubMedCentral
Metadata
Title
FENDRR suppresses cervical cancer proliferation and invasion by targeting miR-15a/b-5p and regulating TUBA1A expression
Authors
Yunheng Zhu
Xiaohua Zhang
Lifeng Wang
Xiuxiang Zhu
Ziyin Xia
Ling Xu
Jun Xu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01223-w

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Spider venom components decrease glioblastoma cell migration and invasion through RhoA-ROCK and Na+/K+-ATPase β2: potential molecular entities to treat invasive brain cancer

Primary research

Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation

Primary research

Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma

Primary research

Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion

Primary research

Circular RNA circ_0020123 promotes non-small cell lung cancer progression by sponging miR-590-5p to regulate THBS2

Primary research

Lattice complex assembled by noncompetitive anti-EGFR antibodies regulates actin cytoskeletal reorganization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits